Close Menu

Optra Health OptraGuru 'Digital Genetic Assistant'

Feb 21, 2018

Optra Health has introduced OptraGuru, an Amazon Alexa-compatible "digital genetic assistant" that allows consumers and healthcare professionals alike to verbally query genetic data. Meant to provide context to consumer genetic tests like those from Ancestry.com and 23andMe, OptraGuru puts the Alexa personal digital assistant on the front end of Optra Health's iPhronesis machine-learning platform to help patients, genetic counselors, and bioinformaticians make sense of genetic test results in a conversational manner.

More Like This

Apr 24, 2019

Human Diagnostics Worldwide, Eiken Chemical, FIND Malaria-LAMP

Human Diagnostics Worldwide, Eiken Chemical, and the Foundation for Innovative New Diagnostics launched Malaria-LAMP for the detection of malaria caused by Plasmodium vivax parasites. The partners said the test is the first commercially available molecular test for P. vivax-associated malaria. It uses loop-mediated isothermal amplification developed by Eiken and is exclusively distributed by Human Diagnostics. FIND and the Hospital for Tropical Diseases evaluated the prototype test and coordinated in-country clinical performance studies in Columbia and Peru. The test can differentiate between Plasmodium pan species, P. falciparum and P. vivax, and has a sensitivity of 84 percent to 94 percent and a specificity of greater than 92 percent. The limit of detection is one to two parasites per microliter. 

Apr 24, 2019

Pacific Biosciences Sequel II System

Pacific Biosciences has launched it Sequel II single-molecule sequencing instrument. The new system runs SMRT chips that contain 8 million wells, or zero mode waveguides, which deliver around eight times greater data output than its original Sequel instrument, which had 1 million ZMWs. According to the company, its HiFi reads, which make use of PacBio's circular consensus sequencing (CCS) protocol, have greater than 99.9 percent accuracy. As of last month, five early access customers had run 58 SMRT cells, obtaining average yields per SMRT cell for the CCS protocol of 250.4 gigabases and average per-cell yields for its continuous long read protocol of 67.4 gigabases.

Apr 23, 2019

Cell Microsystems AIR Software Update, HexaQuad Array

Cell Microsystems has released new software for its AIR system, which automates cloning workflows using brightfield imaging to eliminate the need for fluorescent markers for sorting and confluency measurement. In addition, another new feature automates cell-sorting based on fluorescent signal intensities to characterize complex phenotypes.

Cell Microsystems has also launched the HexaQuad array, which it has designed to simultaneously run 24 distinct experiments on a single consumable. The firm said that the array is suited for labs who perform high-throughput CRISPR editing in single guide or guide pools, which allows for scaling of hundreds of clones per week and reducing a two-month workflow. Combined with the new software, the array provides a five-day workflow for researchers.

Apr 22, 2019

MycoDART MycoDART-PCR

MycoDART has launched MycoDART-PCR, a dual amplification real-time PCR DNA test for the rapid detection of Candida aurus. Pending approval by the US Food and Drug Administration, the test can be ordered currently only through RealTime Laboratories and only with a doctor's order. The launch comes amid reports that C. auris, which is highly resistant to antifungal medications, is spreading throughout the US. C. auris is 1 of 6 Candida species that MycoDART-PCR can detect. It offers a specificity and sensitivity of 95 percent and has been validated for blood, body fluids, and tissue MycoDART said. It can also be run to detect for the presence of C. auris on environmental sufraces. For such purposes, a doctor's order is not needed for the test. 

Apr 18, 2019

Altos, Wasai Accelerated Genome Sequencing Solution

Acer subsidiary Altos Computing and WASAI Technology have globally launched an accelerated sequencing genome solution that will focus on human genome sequencing. The group said the development will integrate Altos' BrainSphere AI computing platform with WASAI's software to create a tool that is faster for genome sequencing without sacrificing accuracy. The joint solution will allow researchers to complete germline analyiss within eight hours. According to the firms, the tool will also help facilities accelerate native algorithms for resutls that are as precise and consistent as the original software. 

Apr 15, 2019

Thermo Fisher Scientific Applied Biosystems QuantStudio 6 and 7 Pro Real-Time PCR Systems

Thermo Fisher Scientific has launched the Applied Biosystems QuantStudio 6 and 7 Pro Real-Time PCR systems. They include smart features such as facial authentication, voice commands, radio-frequency identification (RFID)-enabled plate scanning, and single-touch access to service and support.

Apr 12, 2019

Ares Genetics AresUPA NGS Service

Curetis subsidiary Ares Genetics announced today that it will launch a next-generation sequencing service in mid-2019 using its AresUPA Universal Pathogenome Assay, which can be used to sequence bacterial strains isolated from clinical specimens. According to the firm, AresUPA identifies the bacterial strain and detects antimicrobial resistance based on the genetic profile in the clinical isolate. The assay integrates NGS with data analysis and interpretation powered by ARESdb, the firm's AI-powered reference database on antimicrobial resistance genetics. Ares will offer the assay out of its NGS service laboratory currently being set up in Vienna, Austria. 

Apr 12, 2019

Centogene CentoMetabolic Panel

Centogene has launched its CentoMetabolic panel, a first-line test for a range of rare genetic metabolic diseases. According to Centogene, the panel combines genetic and biochemical testing, allowing immediate confirmation of and better understanding of a disease's course, enhanced treatment monitoring, and tailored treatment guidance. The panel includes as many as 166 genes and was developed for patients suspected to have a metabolic disorder or presenting complex, overlapping symptoms, a metabolic crisis, or neurological conditions of unknown etiology. The firm said that the panel provides short turnaround times, targets critically ill patients, includes enzyme-activity testing and a continually updating set of biomarkers. 

Apr 11, 2019

PetaSuite Protect

PetaGene has introduced PetaSuite Protect, an encryption and access-management system for genomic data. The new product system features Advanced Encryption Standard 256-bit (AES-256) encryption and is compliant with the Federal Information Processing Standard (FIPS) Publication 140-2, a security standard used by the US government. PetaSuite Protect also offers data managers the ability to grant access to specific regions of genomic data files, rather than opening up whole files to all users.

Apr 11, 2019

Enpicom ImmunoGenomiX

Enpicom has introduced ImmunoGenomiX, an immune sequencing data analysis platform. Known as IGX, the platform will help researchers manage, store, analyze, visualize, and interpret immune repertoire sequencing data from T-cell and B-cell receptors. The Netherlands-based company unveiled IGX at the Sixth Immunotherapy of Cancer Conference in Vienna, Austria. 

Apr 09, 2019

Quantabio Qscript lyo 1-step

Quantabio has launched its Qscript lyo 1-step, a lyophilized single-reaction reagent for highly sensitive and reproducible RT-qPCR RNA applications. The firm said that the freeze-dried master mix can be shipped and stored at ambient temperature, which removes the need for cold chain, cuts the carbon footprint, reduces overall costs. Users can store the master mix up to nine months at ambient temperature, or two years at 4 degrees Celsius from the manufacture date. According to the firm, Qscript allows researchers to routinely detect down to 0.5 picograms of RNA. The kit contains a hot-start thermostable polymerase, a genetically engineered reverse transcriptase, as well as other components that the firm said will ensure higher performance detection while multiplexing up to five targets with maximum sensitivity and specificity. The reagent offers high-performance across a range of inputs from 0.5-500 picograms. 

Apr 05, 2019

Fabric Genomics Hereditary Panels With ACE

Fabric Genomics has launched Fabric Hereditary Panels with ACE (AI Classification Engine) software for variant interpretation and clinical reporting. ACE is an artificial intelligence inference engine that leverages deep gene and variant annotation, resulting in highly accurate American College of Medical Genetics variant classification. The software is embedded within the Fabric Enterprise platform for genomic analysis and reporting that delivers a complete sequence-to-clinical report workflow. ACE enhances the Fabric Enterprise platform, making ACMG classification even faster and easier, the company said. The new software is now available for many common genetic tests such as inherited cancer risk including BRCA1 and BRCA2, newborn screening, and CDC-Tier 1 and ACMG incidental findings testing.

Apr 04, 2019

Emedgene Automated Evidence Retrieval

Emedgene has added automated evidence retrieval to its genetic interpretation platform. The new feature relies on natural-language processing to extract knowledge and medical evidence from unstructured text in medical literature. By combining NLP with machine learning, the Emedgene platform can provide actionable insights instead of just search results, the company said.

Apr 02, 2019

Progenity Resura Prenatal Test for Monogenic Disease; Innatal Prenatal Screen

Progenity has launched the Resura prenatal test for monogenic disease, a customizable, noninvasive prenatal test (NIPT) for single-gene disorders. The test is available to families with known risk for monogenic disease such as cystic fibrosis, sickle cell anemia, and Tay-Sachs disease. The test, which was developed using droplet digital PCR, uses fetal cell-free DNA extracted from a sample of the mother's blood, and can be performed on disease-causing variants of all inheritance types, including recessive, dominant, and X-linked genetic mutations.

Progenity also announced improvements to its Innatal prenatal screen, a NIPT for chromosomal aneuploidies that now provides greater specificity and sensitivity in evaluating aneuploidy across all chromosomes. Specifically, the sequencing-based test has been enhanced in terms of detecting aneuploidies in chromosomes 21, 18, 13, X, and Y, the company said.

Apr 02, 2019

PerkinElmer, Helix GenePrism:Actionable Insights

PerkinElmer and Helix have launched GenePrism:Actionable Insights, a genetic screening test that they said is the "most comprehensive clinical grade DNA sequencing and interpretation" test currently on the market. The test allows users to learn about their risk for underlying diseases. A user's DNA will be sequenced by Helix and the results will be interpreted by board-certified geneticists at PerkinElmer Genomics using ordered data interpretation network, that firm's proprietary high-throughput software platform. In comparison to other commercial firms that look at a limited number of letters in a gene sequence, GenePrism:Actionable Insights assesses each of 59 genes in its entirety, including BRCA1/2, the partners said. They also noted that PerkinElmer Genomics maintains one of the largest databases of known genetic variations from different ancestries globally providing customers with a more in-depth assessment. 

The Oregon state Senate unanimously passed a bill that would make it easier for people convicted of crimes to initiate DNA testing of evidence, according to the Associated Press.

People reports that researchers have uncovered genetic variants that lead people to always feel full.

Florida state senators are to weigh a bill prohibiting life insurance companies from using genetic information in coverage decisions, according to Florida Politics.

In Genome Research this week: metagenomic sequencing assay that detects pathogens in cerebrospinal fluid, single-tube long fragment read approach, and more.

May
07
Sponsored by
Agilent

This webinar will discuss the implementation of an enterprise-wide clinical genomics platform that is shared across 10 hospitals and research organizations in the Australian State of Victoria.

Jun
17
Sponsored by
Illumina

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.